HU6

Last updated
HU6
HU6 structure.svg
Legal status
Legal status
  • Investigational
Identifiers
  • 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole
CAS Number
PubChem CID
Chemical and physical data
Formula C11H9N5O7
Molar mass 323.221 g·mol−1
3D model (JSmol)
  • CN1C(=CN=C1[N+](=O)[O-])COC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]

HU6 is a prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider therapeutic index and improve safety." [1] Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for metabolic dysfunction-associated steatohepatitis. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly. [2] [3] A phase 2b trial was launched in late 2023. [4] A phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis was subsequently initiated. [5] Data from this study are expected to be reported in 2025. Additionally, a phase 2a study was performed in patients suffering from heart failure with preserved ejection fraction, a disease that is mediated by visceral fat and obesity. The study achieved the primary endpoint of weight loss, as well as a number of secondary endpoints. [6]

References

  1. ↑ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023). "Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 8 (12): 1094–1105. doi: 10.1016/S2468-1253(23)00198-X . PMID   37806314.
  2. ↑ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology. 21 (8): 2001–2014. doi: 10.1016/j.cgh.2023.03.041 . PMID   37059159.
  3. ↑ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023). "Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 8 (12): 1094–1105. doi: 10.1016/S2468-1253(23)00198-X . PMID   37806314.
  4. ↑ "Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments". Yahoo Finance. 15 November 2023. Retrieved 3 December 2023.
  5. ↑ "Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments". Yahoo Finance. 15 November 2023. Retrieved 3 December 2023.
  6. ↑ "Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related HeartFailure" (PDF). September 30, 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.